MedTrace Logo

Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings

NCT06667206 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2024-10-31

No results posted yet for this study

Summary

This is a phase IIb clinical trial investigating the non-inferiority of immune responses in children given two doses of measles vaccine at different timepoints. The study will randomise 450 children to 3 groups: group A will receive measles containing vaccine (MCV) at 6 and 12 months ; group B at 9 and 18 months; Group C at 6 and 18 months.

Conditions

Interventions

BIOLOGICAL

Licenced Measles-Rubella vaccine

Licenced Measles-Rubella vaccine provided by the Ugandan EPI programme

Sponsors & Collaborators

  • St George's, University of London

    collaborator OTHER

  • MU-JHU CARE

    collaborator OTHER

  • University of Oxford

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
23 Weeks
Max Age
28 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-15
Primary Completion
2026-05-10
Completion
2026-05-10

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06667206 on ClinicalTrials.gov